Abstract 3077: Preclinical studies of SR-8314, a highly selective ENPP1 inhibitor and an activator of STING pathway
Alexis Weston(Translational Genomics Research Institute), Sunil Sharma, Hariprasad Vankayalapti(Translational Genomics Research Institute), Haiyong Han(Translational Genomics Research Institute), Trason Thode(Translational Genomics Research Institute), Sherin Daniel(Translational Genomics Research Institute), Raffaella Soldi(Translational Genomics Research Institute), Rubén M. Muñoz(Translational Genomics Research Institute), Mohan R. Kaadige(University of Utah)
Cited by 1
Related Papers
Blocking Nerve Growth Factor Signaling Reduces the Neural Invasion Potential of Pancreatic Cancer Cells
|PLoS ONE|2016|89
Down-Regulation of Yes Associated Protein 1 Expression Reduces Cell Proliferation and Clonogenicity of Pancreatic Cancer Cells
|PLoS ONE|2012|85
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer
|PLoS ONE|2020|82
Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer
|PLoS ONE|2017|79
Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells
|Prostate Cancer and Prostatic Diseases|2016|47